Business Description
Cloudbreak Pharma Inc
NAICS : 541714
SIC : 2834
ISIN : KYG2215S1084
Total Employee Number:
61Compare
Compare
Traded in other countries / regions
02592.Hong Kong IPO Date
2025-07-03Description
Cloudbreak Pharma Inc is engaged in research and development of ophthalmology biotechnology. The company is a clinical-stage ophthalmology biotechnology company focused on developing treatments for ophthalmic diseases through the proprietary drug discovery and development capabilities, with operations based in the United States and China. The pipeline currently consists of nine drug candidates targeted for treatment of anterior and posterior ophthalmic diseases, including five clinical-stage and four pre-clinical stage candidates. The drugs in the pipeline include CBT-001, CBT-004, CBT-009, and CBT-199.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 76.58 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -8.9 | |||||
3-Year EPS without NRI Growth Rate | -7.9 | |||||
3-Year FCF Growth Rate | -62.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.57 | |||||
9-Day RSI | 46.28 | |||||
14-Day RSI | 46.38 | |||||
3-1 Month Momentum % | -23.57 | |||||
6-1 Month Momentum % | -46.9 | |||||
12-1 Month Momentum % | -76.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.68 | |||||
Quick Ratio | 10.67 | |||||
Cash Ratio | 9.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | -56.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -153.04 | |||||
ROIC % | -42.57 | |||||
3-Year ROIIC % | 38.01 | |||||
ROC (Joel Greenblatt) % | -5375.14 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.18 | |||||
Price-to-Tangible-Book | 2.26 | |||||
EV-to-EBIT | -1.19 | |||||
EV-to-EBITDA | -1.19 | |||||
EV-to-FCF | -1.15 | |||||
| Price-to-Net-Current-Asset-Value | 2.26 | |||||
| Price-to-Net-Cash | 2.54 | |||||
Earnings Yield (Greenblatt) % | -84.03 | |||||
FCF Yield % | -50.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cloudbreak Pharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | |||
| EPS (TTM) (HK$) | -0.982 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 111.66 | ||
| 14-Day RSI | 46.38 | ||
| 14-Day ATR (HK$) | 0.084707 | ||
| 20-Day SMA (HK$) | 1.26475 | ||
| 12-1 Month Momentum % | -76.7 | ||
| 52-Week Range (HK$) | 0.9 - 9.58 | ||
| Shares Outstanding (Mil) | 882.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cloudbreak Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cloudbreak Pharma Inc Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cloudbreak Pharma Inc Frequently Asked Questions
What is Cloudbreak Pharma Inc(HKSE:02592)'s stock price today?
The current price of HKSE:02592 is HK$1.22. The 52 week high of HKSE:02592 is HK$9.58 and 52 week low is HK$0.90.
When is next earnings date of Cloudbreak Pharma Inc(HKSE:02592)?
The next earnings date of Cloudbreak Pharma Inc(HKSE:02592) is .
Does Cloudbreak Pharma Inc(HKSE:02592) pay dividends? If so, how much?
Cloudbreak Pharma Inc(HKSE:02592) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Cloudbreak Pharma Soars 80%+ on Multiple Catalysts, Driving Value Re-Rating | 2025-12-10 |
Articles on Cloudbreak Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers